Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BridgeBio Pharma, Inc. (BBIO) vs Corcept Therapeutics Incorporated (CORT)

BridgeBio Pharma, Inc. and Corcept Therapeutics Incorporated are both Biotechnology companies. BridgeBio Pharma, Inc. and Corcept Therapeutics Incorporated are of similar size ($13.1B and $12.9B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 223×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 16.0%. Corcept Therapeutics Incorporated has the higher net margin (6.53% vs −97.0%) and the higher return on invested capital (1.01% vs 0.00%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 12 and BridgeBio Pharma, Inc. on 6.

Valuation

Metric BBIO CORT Biotechnology median
P/E n/m 223.27 7.88
P/S 18.00 14.73 11.47
P/B n/m 17.33 2.52
Price to free cash flow n/m 114.42 21.16
EV/EBITDA n/m 3,205.62 0.74
EV/Sales 19.70 14.36 10.73
Earnings yield (5.45%) 0.45% (28.84%)
Free cash flow yield (3.46%) 0.87% (23.03%)

Profitability

Metric BBIO CORT Biotechnology median
Gross margin 94.44% 98.30% 65.16%
Operating margin (69.81%) 0.77% 0.00%
Net margin (97.03%) 6.53% 0.00%
Free cash flow margin (61.06%) 12.87% 0.00%
Return on equity 32.31% 8.08% (57.72%)
Return on assets (60.23%) 6.41% (49.22%)
Return on invested capital 0.00% 1.01% 0.00%

Growth

Metric BBIO CORT Biotechnology median
Revenue growth (TTM) 202.39% 16.02% 5.64%
EPS growth (last fiscal year) (31.25%) (33.33%) —
Revenue growth, 5-year CAGR 127.44% 16.56% 8.40%
Net income growth, 5-year CAGR 0.00% (1.52%) 0.00%

Health

Metric BBIO CORT Biotechnology median
Debt to equity (0.77) 0.00 0.00
Current ratio 1.23 2.86 4.73
Net debt to EBITDA (2.47) (8.83) 0.96

Dividend

Metric BBIO CORT Biotechnology median
Dividend yield — 0.31% 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BBIO CORT Biotechnology median
Market cap 13.10b 12.87b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack